Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, was invited to attend the 5th i Hope Medical Oncology Innovation International Forum


As an important guest of the forum, Professor Shi Yuanyuan, chairman of the board, delivered a speech on the theme of "Research Progress of NK and CAR-NK Cell therapy", introduced the current international research progress of NK and CAR-NK therapy in detail, and also introduced the latest progress and breakthroughs made by Shenzhen Cell Valley in this field, which was highly recognized by clinical experts of various schools. Professor Shi Yuanyuan pointed out that natural killer cells (NK cells) account for 5% to 15% of adult peripheral blood lymphocytes and are important innate immune cells. NK cells play a key role in tumor immune surveillance and kill tumor cells by directly dissolving and secreting cytokines. The main goal of NK cell therapy is to improve a patient's ability to fight cancer or other diseases by activating or enhancing the function of NK cells. CAR-NK has better efficacy in the treatment of hematoma and solid tumor, and has the advantages of high industrial production capacity, low cost and side effect risk. Although CAR-NK has great application prospects, there are still some major card points that hinder its successful application in the clinical side. Shenzhen Cell Valley one-on-one to solve various difficulties of CAR-NK - low transduction efficiency, difficult production and proliferation, poor sustainability, to solve the limitations of clinical transformation of CAR-NK cells. At the same time, Shenzhen Cell Valley has owned independent intellectual property rights of the development and industrial application of BaEV coated retrovirus packaging engineering cell lines, the positive rate of transducing T cells and NK cells is more than 90%, and the positive rate has not decreased.

In the answer to expert questions and answers, a number of clinical medical experts asked Professor Shi Yuan for advice on the advantages of allogeneic NK cells and cell therapy policies. Professor Shi Yuanyuan shared that APUNK™, a non-modified allogeneic NK cell launched by Shenzhen Cell Valley, can multiply more than 10,000 times in vitro, which can meet the number of cells required for clinical infusion. The purity of the prepared NK cells was greater than 99%, and the T cells < 0.1%, which was much higher than the allograft standard recognized by the US FDA (NK cells > 90%, T cells < 5%). In addition, he elaborated the historical development of cell therapy-related policies. As a legislative consulting expert on the Regulations on the Promotion of Cell and Gene Industry in Shenzhen Special Economic Zone and the Regulations on the Promotion of Cell and Gene Industry in Xiamen Special Economic Zone, Professor Shi Yuanyuan foresaw the future of policy development with great foresight.
